# Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury

> **NCT05217498** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Randy Trumbower, PT, PhD** · enrollment: 40 (estimated)

## Conditions studied

- Spinal Cord Injuries
- Myelopathy

## Interventions

- **DRUG:** Istradefylline
- **DEVICE:** low oxygen therapy

## Key facts

- **NCT ID:** NCT05217498
- **Lead sponsor:** Randy Trumbower, PT, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-09-01
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05217498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05217498, "Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05217498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*